Status
Conditions
Treatments
About
The primary objective is to compare the effectiveness of the experimental Intermittent Colonic Exoperistalsis (ICE) treatment with MOWOOT, with the active control of trans-anal irrigation (TAI) as standard-of-care. The secondary objectives are to further compare the ICE treatment with MOWOOT to the TAI standard-of-care clinically and economically.
Full description
The RCT will assess clinical effectiveness by means of quantitative and qualitative variables, and the cost effectiveness by means of economic outcomes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Disease phenotype exclusion criteria:
Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)
Inflammatory Bowel Disease (IBD)
Device-related exclusion criteria:
Abdominal perimeter ≤65cm or ≥130cm
Unable to independently use the MOWOOT or TAI technology, unless a carer is available daily to assist
Other medical conditions, medications and contraindications:
Previous large bowel resection
The presence of a stoma
External rectal prolapse
Active anorexia or bulimia
Active abdominal cancer
Large inguinal or umbilical hernia
Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable
Pregnancy or attempt to become pregnant in the next 6 months
Use of strong opioids*
Use of antidepressants, bladder stabilisers or any other medication inducing, or treating, constipation unless used at a stable dose for at least 4 weeks before Screening Visit (this excludes laxatives which may be used as required up to three days before the screening visit)
Subjects already undertaking or have undertaken abdominal massage unless they underwent a previous washout period of at least 2 months
Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial
Planned surgery for constipation if it might be within trial dates
Primary purpose
Allocation
Interventional model
Masking
86 participants in 2 patient groups
Loading...
Central trial contact
Immaculada Herrero, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal